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Helodermin is a biologically active peptide isolated from the venom of the Gila monster lizard (Heloderma 
suspectum) whose structure is related to that of vasoactive intestinal peptide and secretin. Using a specific 
radioimmunoassay based on antisera prepared by immunizing rabbits with natural helodermin, we demon- 
strated the presence of helodermin-like material in mammalian salivary glands, including parotid, sub- 
maxillary and sublingual glands from rat and dog, and parotid and submaxillary glands from man. All helo- 
dermin-like materials had an apparent molecular mass of 4-12 kDa. Dog saliva, collected after pilocarpine 
stimulation, revealed similar immunoreactivity with a major component around 6 kDa. 
Helodermin Gila monster venom Secretin/ VIP peptide family Mammalian salivary gland Saliva 
1. INTRODUCTION 
The presence, in the venom of Gila monster 
lizard (Heloderma suspectum), of a biologically 
active material closely related to peptides of the 
vasoactive intestinal peptide (VIP)/secretin/PHI 
family was discovered by Raufman et al. [l] and 
further substantiated by Amiranoff et al. [2] and 
our group [3,4]. The purification to homogeneity 
of this material was recently achieved [5,6] and the 
amino acid sequence determined independently by 
two groups of investigators [6,7]. The acronym 
helospectin was given by Parker et al. [6] to pep- 
tides with 37 and 38 amino acid residues and the 
acronym helodermin was proposed by our group 
to a 35 amino acid peptide [7]. The sequences of 
helodermin, helospectins, VIP, PHI, secretin, 
GRF and glucagon are compared in table 1. It is 
not yet clear whether helodermin and helospectin 
* TO whom correspondence should be addressed 
represent, indeed, distinct molecular species. We 
have now identified the presence of helodermin- 
like material in the salivary glands of mammals, 
using a specific radioimmunoassay. 
2. MATERIALS AND METHODS 
Salivary glands obtained from rat, dog and man 
were immediately frozen in liquid nitrogen. They 
were later homogenized in distilled water with an 
Ultraturrax and immediately immersed in a boiling 
water bath for 5 min. After cooling, the 
homogenate was mixed with an equal volume of 
1.0 M acetic acid. After centrifugation, the super- 
natant was lyophilized then dissolved in either the 
radioimmunoassay buffer or in the buffer used for 
the chromatographic procedure (see below). 
Antisera were prepared by immunizing three 
rabbits with natural pure helodermin [5] coupled 
to bovine serum albumin by 1-ethyl-3-(3-dimeth- 
ylaminopropyl)carbodiimide. One rabbit pro- 
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duced, after the third immunization, antiserum 
(15-3) that was sufficiently active to be used for 
radioimmunoassay. [1251]Iodohelodermin was 
prepared as described [8]. 
Radioimmunoassay was routinely performed in 
plastic tubes with a buffer system made of 0.01 M 
sodium phosphate (pH 7.5) completed with 0.9% 
sodium chloride, 0.1% sodium azide and 0.05% 
Tween 20. The incubation started with 0.2 ml of 
the sample dissolved in assay buffer and 0.3 ml of 
antiserum to helodermin (diluted 15 000-fold with 
the assay buffer) and enriched with 0.2% normal 
rabbit serum. After 16-20 h at 4”C, 0.05 ml 
[1251]iodohelodermin assay buffer (+ 10000 
cpm/tube) were added and the incubation was con- 
tinued at 4°C for a further 40 h period. Bound and 
free labelled peptides were separated by a second 
antibody precipitation method with sheep anti- 
rabbit y-globulins, the precipitation being enhanced 
by adding 3.3% polyethylene glycol [9]. 
The main characteristics of the assay are il- 
lustrated in fig. 1. Antiserum 15-3 reacted with 
natural helodermin, synthetic (l-37)-NH2 heloder- 
min, and the (l-27)-NH2 helodermin fragment. 
Five synthetic C-terminal fragments of helodermin 
[(7-35)-NH2, (13-35)-NHz, (17-35)-NH2, (18-35)- 
NH2 and (22-35)-NH2], tested at concentrations 
lOO-fold higher than that allowing the recognition 
of the complete helodermin sequence, were not 
recognized by the antibodies, indicating that an- 
tiserum 15-3 was specific for the N-terminal part of 
helodermin. No cross reaction was observed with 
parent neurohormones and a few unrelated pep- 
tides, including chicken and porcine VIP, porcine 
secretin, porcine glucagon, porcine PHI, human 
GRF( l-40)-OH (kindly given by Dr J. Rivier), 
human GRF(l-29)-NH2 (kindly given by Dr D. 
Coy), apamin, CCK-8, prolactin, and pancreatic 
polypeptide all tested at a dosis of 100 rig/assay.. 
3. RESULTS AND DISCUSSION 
The acidic extracts obtained from parotid, sub- 
lingual, and submaxillary glands from rat and dog, 
as well as those prepared from human parotid and 
submaxillary glands (surgically removed for 
lithiasis) inhibited dose-dependently the binding of 
[‘2’I]iodohelodermin to antiserum 15-3. A typical 
example is given in fig. 1 (panel B) with an extract 
of dog submaxillary gland. The competition curve 
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Fig. 1. Main characteristics of the antihelodermin 
antiserum (15-3) utilized at a final 1: 30000 dilution. The 
radioactivity bound (Bo) represented 37.8% of the 
radioactivity offered. The helodermin concentration 
required for 50% reduction of tracer binding (I&) was 
23.0 + 1.2 pg/assay (mean + SE of 22 determinations) 
and the limit of detectability was 2 pg/assay. Specificity 
was tested comparing natural helodermin (o), fragment 
(7-35)-NH2 (0), fragment (13-35)-NH2 (x), and 
fragments (17-35)-NH2, (18-35)-NHz, and (22-35)-NH2 
(0) of helodermin to a dog submaxillary gland extract 
(A). VIP, secretin, glucagon, GRF(l-40)-OH, 
GRF(l-29)-NH2 and PHI (n) were also tested. Average 
values of 2 experiments. 
was not parallel to that of the reference peptide, 
preventing a precise estimation of the im- 
munoreactive helodermin-like material. Similar 
results were obtained with all tissue samples tested. 
Considering the amount of extract provoking 50% 
inhibition of tracer binding, we tentatively 
estimated the concentration of helodermin-like 
material in rat and dog salivary glands to range 
from 2 to 8 rig/g wet wt tissue. In 4 pathological 
specimens of human salivary glands these values 
ranged from 0.8 to 8 rig/g wet wt tissue. 
Acidic extracts of submaxillary glands were sub- 
mitted to gel permeation chromatography on a 
TSK-G 2000 SW column of a model used to purify 
helodermin [5]. The column was eluted at 
0.1 ml/min with 30% 1-propanol in 0.4 M am- 
monium acetate (pH 7.0) and 5 min fractions were 
collected. The fractions were evaporated and the 
dry residue, dissolved in assay buffer, was 
radioimmunoassayed with antiserum 15-3. Typical 
chromatograms of samples from submaxillary 
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glands of rat, dog and man are illustrated in fig.2. 
In the rat submaxillary extract, the rather asym- 
metrical peak suggested the coexistence of a major 
component of about 6 kDa with a larger molecular 
mass component. With dog submaxillary extract, 
the major peak eluted in the 12 kDa position but 
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Fig.2. Gel permeation chromatography on TSK-G 2000 
column of boiled acidic extracts corresponding to 250, 
150 and 140 mg wet wt of subm~illary glands from, 
respectively, rat (panel A), dog (panel B), and human 
(panel C). The human specimen corresponded to a 
macroscopically intact area from a calculous gland. 
Elution was performed at a rate of 0.1 ml/min. 5 min 
fractions were collected and lyophilized; the residue was 
dissolved in 1.0 ml of assay buffer, 0.2 ml aliquots being 
used for radioimmunoassay with antiserum 15-3. 
Column calibration, as indicated by the arrows, was 
performed under similar experimental conditions with 
bovine serum albumin (67.0 kDa), myoglobin 
(17.8 kDa), cytochrome c (12.4 kDa), insulin (6.0 kDa), 
helodermin (3.8 kDa), insulin chain A (2.5 kDa) and 
bacitracin (1.5 kDa). 
significant immunoreactivity was also present in 
the 6 kDa position. With human submaxillary ex- 
tract, the main immunoreactive peak eluted with 
an apparent molecular mass between 4 and 6 kDa. 
Thus, in ali salivary glands tested, the helodermin- 
like material had an apparent molecular mass of 
4-12 kDa i.e, a molecular mass slightly higher 
than that of the reference helodermin from the 
venom of Gila monster lizard. 
Besides, a sample of dog saliva, consisting most- 
ly of sublingual and submaxillary secretions col- 
lected after stimulation with an i.m. injection of 
the muscarinic agonist pilocarpine, revealed after 
chromatography, a composite immunoreactive 
peak with a major component around 6.0 kDa 
(fig.3). 
The preceding data did not reflect tracer 
degradation: [‘2’I]iodohelodermin remained stable 
(i.e. 90% precipitable by 5% trichloroacetic acid) 
in paraliel incubations of tracer and tissue or saliva 
extracts, conducted under the radioimmunoassay 
conditions. 
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Fig.3. Gel permeation chromatography on TSK-G 2000 
column of a boiled acidic extract corresponding to 
0.5 ml of dog saliva collected at the ostium of the 
common duct of sublingual and submaxillary glands, 
after i.m. injection of 10 mg pilocarpine. The dog was 
anesthetized with nembutal. Saliva was collected over ice 
then boiled for 5 min. After cooling, an equal volume of 
1 M acetic acid was added and the sample was 
centrifuged. The supernatant was lyophilized. The 
residue corresponding to 0.5 ml saliva was dissolved in 
the elution chromatographic buffer (see fig.2) and 
chromatographed. 5 min fractions were lyophilized, 
then dissolved in I.0 mi assay buffer, 0.2 ml aliquots 
being used for radioimmunoassay with antiserum 15-3. 
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Table 1 
Comparison of the amino acid sequence of helodermin with other members of VIP family 
Helodermin 
Helospectin(s) 
VIP (porcine) 
PHI (porcine) 
Secretin (port) 
GRF(1-44) (hum) 
Glucagon (port) 
1 5 10 15 20 25 30 35 40 45 
H-S-D-A-I -F-T-Q-Q-Y-S-K-L-L-A-K-L-A-L-Q-K-Y-L-A-S-I -L-G-S-R-T-S-P-P-P-OH 
H -S -D -A-T -F -T -A -E -Y -S -K -L -L -A -K -L -A -L -Q -K -Y -L -E -S -I -L -Cl -S -S -T -S -P -R -P -P -S -(S) 
H-S -D -A-V -F -T -D -N -Y -T -R -L -R -K -Q -M-A -V -K -K -Y -L -N -S -1 -L -N -OH 
H-A-D-G-V-F-T-S-D-F-S-R-L-L-G-Q-L-S-A-K-K-Y-L-E-S-L-I 
H-S -D -G -T -F -T -S -E -L -S -R -L -R -D -S -A -R -L -Q -R -L -L -Q -G -L -V -OH 
Y -A-D -A -I -F -T -N-S -Y -R -K -V -L -G -Q -L -S -A-R -K -L -L -Q -D -1 -M-S -R -Q -Q-G-E -S -N -Q -E -R 0 -A -R -A -R -L 
H-S -Q-G-T -F -T -S -D-Y -S -K -Y -L -D -S -R -R -A-Q -F -V -Q -W-L -M-N -T 
We have thus established, by radioim- 
munoassay, that: (i) a group of peptides, im- 
munologically related to helodermin (a biologically 
active peptide of the VIP/secretin/PHI/glucagon/ 
GRF family present in the venom of Helodermae 
lizards), is present in mammalian salivary glands; 
(ii) these peptides are secreted in the oral cavity of 
mammals as well as a venomous lizard. 
The sequence homology (table 1) between an ex- 
ocrine secretory product such as lizard helodermin 
(and probably also its mammalian counterpart) on 
the one hand, and circulating hormones and/or 
neurotransmittors on the other supports the view 
of a unitary origin for exocrine and endocrine 
functions [lo]. Examples of humoral messenger 
molecules appearing in exocrine secretions are 
relatively rare: epidermal growth factor produced 
by rodent salivary glands is preferentially secreted 
in saliva [ 1 l-131 and contributes slightly to cir- 
culating levels [14]; VIP, somatostatin and gastrin 
are found in gastric, pancreatic and intestinal 
secretions [ 151 but this represents probably an 
‘overflow’ of neurohormonal secretion rather than 
direct exocrine secretion. 
Due to the high degree of homology between 
helodermin and the other members of the VIP 
family, the new peptide could, conceivably, 
represent mere ontogenic variant(s) of a well 
known model. The structure of each peptide of this 
family is, however, so conservative throughout 
evolution that helodermin might also be the pro- 
totype of a new class of regulatory peptides. Here 
we support the latter hypothesis by showing that 
helodermin-like material is present in large 
amounts in the salivary secretion and that the 
salivary glands are the main source of this material 
in both dog and man. These helodermin-like pep- 
tides represent original molecules, closely related 
yet different from other peptides of the VIP family 
considering that: (i) The antiserum utilized 
recognized preferentially the N-terminal portion of 
helodermin that displays the highest sequence 
homology with VIP, secretin, PHI, glucagon and 
GRF (more than 50% homology when considering 
the 1-15 sequence only; table 1). This N-terminal 
portion is critical for the biological activity of these 
peptides [16-191; (ii) VIP, secretin, PHI, glucagon 
and GRF did not cross react with antihelodermin 
antiserum at a concentration of 100 rig/assay;; (iii) 
VIP and PHI in mammalian salivary glands are 
strictly confined to nerve endings and ganglia 
[20,21]; (iv) it was previously reported that im- 
munoreactive glucagon abounded in salivary 
glands [22-241 but this proved to be an artifact due 
to rapid tracer degradation by proteases during the 
radioimmunoassay [25]. Besides, glucagon cannot 
be demonstrated in salivary glands by im- 
munohistochemcal techniques [26]; (v) the 
presence of secretin and GRF [27] has never been 
documented in salivary glands. 
To attribute a precise role to the helodermin 
class of peptides will require: (i) the identification 
of helodermin in neurohormonal cells in the Gila 
monster lizard itself and (ii) the purification and 
chemical characterization of the helodermin-like 
material presently identified in mammals, as well 
as the appreciation of its distribution and 
biological activity. 
ACKNOWLEDGEMENTS 
We thank Professor R. Mayer (Hopital Univer- 
sitaire Saint-Pierre, Brussels, Belgium) for his help 
in collecting the human specimens tested. This 
work was supported by grant 5 ROI-AM 17010-7 
from the National Institutes of Health (USA) and 
145 
Volume 190, number 1 FEBS LETTERS October 1985 
by a ‘Concerted action’ from the Ministry of 
Scientific Policy (Belgium). 
REFERENCES 
111 
PI 
[31 
[41 
I51 
161 
171 
VI 
[91 
1101 
[ill 
Raufman, J.-P., Jensen, R.T., Sutliff, V.E., 
Pisano, J.J. and Gardner, J.D. (1982) Am. J. 
Physiol. 242, G470-G474. 
Amiranoff, B., Vauclin-Jacques, N., Boige, N., 
Rouyer-Fessard, C. and Laburthe, M. (1983) FEBS 
Lett. 164, 299-303. 
Gillet, L., Robberecht, P., Waelbroeck, M., 
Camus, J.C., De Neef, P., K&rig, W. and 
Christophe, J. (1984) Peptides 5, 407-409. 
Robberecht, P., Waelbroeck, M., Dehaye, J.P., 
Winand, J., Vandermeers, A., Vandermeers-Piret, 
M.-C. and Christophe, J. (1984) FEBS Lett. 166, 
277-282. 
Vandermeers, A., Vandermeers-Piret, M.-C., 
Robberecht, P., Waelbroeck, M., Dehaye, J.-P., 
Winand, J. and Christophe, J. (1984) FEBS Lett. 
166, 273-276. 
Parker, D.S., Raufman, J.P., O’Donohue, T.L., 
Bledsoe, M., Yoshida, M. and Pisano, J.J. (1984) 
J. Biol. Chem. 259, 11751-11755. 
Hoshino, M., Yanaihara, C., Hong, Y.-M., 
Kishida, S., Katsumaru, Y., Vandermeers, A., 
Vandermeers-Piret, M.-C., Robberecht, P., 
Christophe, J. and Yanaihara, N. (1984) FEBS 
Lett. 178, 233-239. 
Robberecht, P., Waelbroeck, M., De Neef, P., 
Camus, J.C., Vandermeers, A., Vandermeers- 
Piret, M.-C. and Christophe, J. (1984) FEBS Lett. 
172, 55-58. 
Pandian, M.R., Horvat, A. and Said, S.I. (1982) 
in: Vasoactive Intestinal Peptide (Said, S.I. ed.) 
pp.35-50, Raven, New York. 
Roth, J., Le Roith, D., Shiloach, J., Rosenzweig, 
J.L., Lesniak, M.A. and Havrankova, J. (1982) 
New Engl. J. Med. 306, 523-527. 
Roberts, M.L. (1974) Biochem. Pharmacol. 23, 
3305-3308. 
WI 
1131 
[I41 
1151 
[I61 
1171 
V81 
1191 
WI 
WI 
WI 
v31 
v41 
v51 
WI 
v71 
Roberts, M.L. (1978) Biochim. Biophys. Acta 540, 
246-252. 
Murphy, R.A., Saide, J.D., Blanchard, M.H. and 
Young, M. (1977) Proc. Natl. Acad. Sci. USA 74, 
2672-2676. 
Murphy, R.A., Saide, J.D., Blanchard, M.H. and 
Young, M. (1977) Proc. Natl. Acad. Sci. USA 74, 
2330-2333. 
Uvnas-Wallenstein, K. (1977) in: Gut Hormones 
(Bloom, S.R. ed.) pp.389-393, Churchill 
Livingston, Edinburgh. 
Bregman, M.D., Trivedi, D. and Hruby, V.J. 
(1980) J. Biol. Chem. 255, 11725-11731. 
Robberecht, P., Conlon, T.P. and Gardner, J.D. 
(1976) J. Biol. Chem. 251, 4635-4639. 
Christophe, J.P., Conlon, T.P. and Gardner, J.D. 
(1976) J. Biol. Chem. 251, 4629-4634. 
Couvineau, A., Rouyer-Fessard, C., Fournier, A., 
St-Pierre, S., Pipkorn, R. and Laburthe, M. (1984) 
Biochem. Biophys. Res. Commun. 121, 493-498. 
Lundberg, J.M., Angglrd, A., Fahrenkrug, J., 
Hdkfelt, T. and Mutt, V. (1980) Proc. Natl. Acad. 
Sci. USA 77, 1651-1655. 
Wharton, J., Polak, J.M., Bryant, M.G., Van 
Noorden, S. and Bloom, S.R. (1979) Life Sci. 25, 
273-280. 
Lawrence, A.M., Tan, S., Hojvat, S. and Kirsteins, 
L. (1977) Sciences 195, 70-72. 
Bhathena, S.J., Smith, S.S., Voyles, N.R., Penhos, 
J.C. and Recant, L. (1977) Biochem. Biophys. Res. 
Commun. 74, 1574-1581. 
Perez-Castillo, A. and Blazquez, E. (1980) 
Diabetologia 19, 123-129. 
Tahara, Y., Shima, K., Hirota, M., Ikegami, H., 
Tanaka, A. and Kumahara, Y. (1983) Biochem. 
Biophys. Res. Commun. 113, 340-347. 
Barka, T. (1980) J. Histochem. Cytochem. 28, 
836-859. 
Shibasaki, T., Kiyosawa, Y., Masuda, A., 
Nakahara, M., Imaki, T., Wakabayashi, I., 
Demura, H., Shizume, K. and Ling, N. (1984) J. 
Clin. Endocrinol. Metab. 59, 263-268. 
146 
